Ethorobotic rats for rodent behavioral research: design considerations.

The development of robots as tools for biological research, sometimes termed "biorobotics", has grown rapidly in recent years, fueled by the proliferation of miniaturized computation and advanced manufacturing techniques. Much of this work is focused on the use of robots as biomechanical models for natural systems. But, increasingly, biomimetic robots are being employed to interact directly with animals, as component parts of ethology studies in the field and behavioral neuroscience studies in the laboratory.

Air-to-land transitions: from wingless animals and plant seeds to shuttlecocks and bio-inspired robots.

Recent observations of wingless animals, including jumping nematodes, springtails, insects, and wingless vertebrates like geckos, snakes, and salamanders, have shown that their adaptations and body morphing are essential for rapid self-righting and controlled landing. These skills can reduce the risk of physical damage during collision, minimize recoil during landing, and allow for a quick escape response to minimize predation risk. The size, mass distribution, and speed of an animal determine its self-righting method, with larger animals depending on the conservation of angular momentum and smaller animals primarily using aerodynamic forces.

The Natural Robotics Contest: crowdsourced biomimetic design.

Biomimetic and bioinspired design is not only a potent resource for roboticists looking to develop robust engineering systems or understand the natural world. It is also a uniquely accessible entry point into science and technology. Every person on Earth constantly interacts with nature, and most people have an intuitive sense of animal and plant behaviour, even without realizing it.

Selpercatinib Treatment of RET-Mutated Thyroid Cancers Is Associated With Gastrointestinal Adverse Effects.

Context: Metastatic medullary thyroid carcinoma (MTC) and radioactive iodine-refractory differentiated thyroid carcinoma (RAI-R DTC) have poor prognosis and limited treatment options. Selpercatinib (LOXO-292), a selective kinase inhibitor targeting the RET gene, has shown a 69% to 79% objective response rate in this cohort with benefits in other tumors including lung cancer harboring the same oncogenic driver. Published reports describe only 17% of patients experiencing gastrointestinal (GI) adverse effects (AEs), which is in contrast to our local experience.